Ask Question
Sign Guest book

 
About Lymphoma
| Advocacy & Art | CAM & Life Style | Clinical trials | Doctors & Centers  | Guidelines  at  Diagnosis | How  to   Help  | Research | Side Effects  | Support | Symptoms  | Tests | Treatments


WebCasts

Clinical Trials by Treatment Type

  

ClinicalTrials.gov > Lymphoma type | Treatment type | Other | State or Country | Trials of Interest
About Trials | Expanded Access | Other Trial Resources | PDQ Services | Travel for Treatment

Clinical Trials > By Treatment OR Target type

Last update: 05/12/2008

  Antiangiogenesis | anti-apoptosis inhibitors | Antibodies | Antibodies & Biologics without chemoAntisense (anti-bcl-2) | Arsenic Trioxide | Bexxar | BendamustineBMS-247550Bryostatin | Chemotherapy | Enzastaurin | Enzyme inhibiting therapies | Gallium Nitrate | GvHD | HDAC inhibitors | Immune-based | Liposomal Agents | mTOR | ONTAK | Pixantrone | Radiotherapy | RadioimmunotherapyRevlimid (lenalidomide) | SGN-30 Stem Cell transplants | Vaccines | Velcade - proteasome inhibitor | Zevalin | Other | Also see Pipeline

or select from menu: 

Click here to request a trial search.
Antiangiogenesis 
Return to top
Antiangiogenesis therapies  
 
The goal is to target the blood supply that feeds tumors.
 
Vorinostat  (suberoylanilide hydroxamic acid - SAHA)

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

More agents of this type...
anti-apoptosis inhibitors

agents that target pathways in malignant cells that resist apoptosis

anti-apoptosis inhibitors, copied from Pipeline
 
ABT-263  | APO866 | AT-101 | GMX1777 | GX15-070 | YM155
Antibodies (monoclonal)

with or without chemotherapy

Return to top
Antibodies (monoclonal) with or without chemotherapy

Targets a specific receptor type on the surface of malignant cells 
HuMax-cd20 

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

Rituxan (Rituximab)

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

Bispecific antibodies
Targets two receptor types on the malignant cells with one antibody

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

Antibodies & Biologics

excluding chemotherapy

Return to top
Antibodies (monoclonal) 

"Antibodies
excluding chemo ...  for previously untreated patients
excluding chemo and radioimmunotherapy
excluding chemo, radioimmunotherapy and Rituxan
Next generation CD20 targeting, but not Rituxan (edited Oct 2007)

NOTE:  Many next-generation anti-cd20 Mabs are emerging.
Biologics - Cytokines | Biological response modifiers
BL22 

BL22 immunotoxin can find tumor cells that express cd22 and kill them without harming normal cells.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
   

Antigen-specific antibodies:
Anti-Tac (for Tac-expressing lymphoma, including T-cell NHL)

Daclizumab (t-cell lymphomas)

CD22-targeting
Rituxan  (CD20 targeting)
Antibodies combined with biologics: 
IL-2IL-12 | CpG | Anti-cd80 antibody - IDEC-114 
Antisense | G-CSF (Neupogen)
GM-CSF (Leukine)

TOPIC SEARCH: Mechanisms with Rituxan PubMed 
Outcome with Rituxan ASCO | Medscape | PubMed
Safety ASCO | PubMed 
  

Antisense (anti-bcl-2)
Return to top
Antisense (anti-bcl-2)  (Oblimersen sodium, Genasense)
 
Antisense therapy inhibits cell production of bcl-2, a protein that is thought to inhibit cell death and increase resistance to cancer therapies.  Thus, the goal of antisense therapy is to sensitize cancer cells to cancer treatments. It may also have activity as a single agent.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
  

Arsenic Trioxide
Return to top
Arsenic trioxide
 
Arsenic trioxide may induce cell death (apoptosis) and normalization (differentiation) thru novel pathway(s). Approved for leukemia.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

Bendamustine
BMR effective - ASH 2006

B + R - ASH 2006
Return to top
Bendamustine 
 
Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazol group.  It has shown activity against refractory lymphomas - lymphomas resistant to treatment.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

Bexxar
 
 
Return to top
Bexxar (Tositumomab, Iodine I 131)
 
Radioimmunotherapy for CD20 positive lymphomas.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 

Also see Radiolabeled Antibodies
BMS-247550
Return to top
BMS-247550 
 
Epothilone B-Analog. Primarily for relapsed aggressive lymphomas.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
  

Bryostatin
Return to top
Bryostatin 
 
Possible mechanism of action: "Bryostatin-1 is believed to bind to the regulatory domain of the PKC enzyme suggesting a mechanism of action distinct from other kinase modulators in development." - gpc-ag.com

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
  

Chemo agents 
And not Transplant
Also see Liposomal chemotherapy below.
 Related topics:

Chemotherapy
 
Return to top
Chemotherapy-based treatment: All phases | Phase I | Phase II | Phase III  

Chemotherapy is a general term for a systemic therapy. 

Click here for details on meaning of Phase I, II, III studies.
Chemotherapy with biologics 
High Dose Cytoxan and biologics (by request) 
Enzyme inhibiting therapies
 Related topics:

Enzyme therapy
 
Return to top

 

Enzyme Inhibiting Therapies
Enzastaurin
Return to top
Enzastaurin
Enzastaurin (LY317615), an acyclic bisindolylmaleimide, is an oral inhibitor of the protein kinase Cbeta isozyme.
Graft vs Host Disease
 Related Abstracts:

Graft vs Host | Novel
 
Return to top
Graft versus Host disease 
acute GvHD  | chronic GvHD  
 
Graft vs. Host Disease (GvHD) -  a frequent complication of allogeneic bone marrow transplant in which the donor's bone marrow cells attacks the patient's organs and tissue. GvHD tends to be more severe in patients receiving mismatched transplants from family member and in patients receiving unrelated donor transplants.  See GvHD for more detail.
Immune-based therapies
 Related Abstracts:

general

 vaccines
 
Return to top
Immunotherapy without chemo or radiotherapy | phase I for this type
CTLA4 
EBV-specific lymphocyte therapy
Peripheral blood lymphocyte therapy 
Immune-modulator therapy without chemotherapy
 
The goal of this investigative treatment type is to modify the immune system in order to fight lymphoma or enhance other treatments.

Also see Vaccine below

Gallium Nitrate
Ganite
Return to top
Gallium Nitrate
 
The goal is induce lymphoma cell death, selectively.  Trials appear to be closed as of 11/2005.  Outcome data has not been presented yet.
Histone deacetylase (HDAC) inhibitor 
Related Abstracts:

HDAC
 
Return to top
HDAC inhibitors
 
"HDAC inhibitor MS-275, a benzamide derivative, has demonstrated potent and unique cytotoxicity and anticancer activity in vitro (test tube) in human tumor cell lines and, more importantly, in vivo in human tumor xenografts." 
kinase inhibitors 

 

All studies for
tyrosine kinase inhibitors
Lenalidomide
(CC-5013, Revlimid)
 
 
immune modulation (IMiD)
Return to top
All studies for 

"Lenalidomide...  may decrease the production of cytokine and growth factors decreasing the growth of the cells or new blood vessels for the cells. ...  it could also improve the function of natural killer T cells, and enhance immunity.

Lenalidomide is currently approved by the FDA for the treatment of multiple myeloma, another type of cancer that affects circulating plasma cells, which produce antibodies. Lenalidomide is currently awaiting FDA approval for CLL and NHL."

Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 

Liposomal 
Delivery of Drugs
 Related Abstracts:

liposomal doxorubicin 
 
liposomal vincristine 
 
liposomal antisense

Topics:

 Liposomal chemo
Return to top
Liposomal versions of biologics and chemotherapy
 
Liposomal delivery of treatments may reduce side effects and/or improve efficacy.
Motexafin Gadolinium
(Xcytrin)
 Related Abstracts:

Motexafin Gadolinium
 
Return to top

 

Motexafin Gadolinium 
 
A radio-sensitizing agent that combines preferential tumor uptake with detection of drug localization by magnetic resonance imaging.
mTOR inhibitors
All for lymphomas
ONTAK
(denileukin diftitox)
 Related Abstracts:

ONTAK
 
Return to top
ONTAK
  
Ontak is a fusion protein which adheres to the interleukin-2 receptor on the malignant cell which may cause cell death.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 

Pixantrone
 Related Abstracts:

 Pixantrone 
 
Return to top
Pixantrone 
 
Might have similar activity against aggressive lymphomas as doxorubicin, with less cardio toxicity. -  prnews 
Radiotherapy 
 Related Abstracts:

  radiotherapy
 
Return to top

 

Investigational therapies:
Radiotherapy all stages - Stage I | Stage II | Stage III | Stage IV
Excluding chemotherapy